Skip to main content
Normal
Press Release RSS Feed (opens in new window)
Press Releases
Press release year list
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
December 20, 2019
Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
December 19, 2019
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020
December 18, 2019
Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
December 13, 2019
Bristol-Myers Squibb Announces Leadership Changes
December 10, 2019
Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
December 9, 2019
Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
December 8, 2019
Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting
December 7, 2019
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
December 7, 2019
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
December 6, 2019
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
December 6, 2019
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
December 5, 2019
Bristol-Myers Squibb Announces Dividend Increase
December 4, 2019
Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant
December 3, 2019
Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes
November 26, 2019
Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights
November 21, 2019
Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes
November 20, 2019
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
November 20, 2019
Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%
November 15, 2019
Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
November 15, 2019
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition
November 15, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
November 12, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
November 11, 2019
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma
November 7, 2019
Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting¹
November 7, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
November 5, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
November 1, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
October 31, 2019
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 30, 2019
Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference
October 30, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
October 30, 2019
Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT
October 24, 2019
European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
October 22, 2019
CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
October 18, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
October 8, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
September 30, 2019
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
September 28, 2019
Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
September 28, 2019
Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients
September 28, 2019
Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
September 24, 2019
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...
September 23, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
September 20, 2019
Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights
September 19, 2019
Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers
September 12, 2019
Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019
September 11, 2019
Bristol‑Myers Squibb Announces Dividend
September 10, 2019
Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
September 5, 2019
Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
September 4, 2019
More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research
September 3, 2019
Bristol-Myers Squibb to Take Part at the Morgan Stanley Conference
August 27, 2019
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
August 26, 2019
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
July 29, 2019
Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
July 26, 2019
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
July 25, 2019
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 24, 2019
Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
July 24, 2019
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
July 18, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer
July 1, 2019
Bristol-Myers Squibb Completes Divestment of UPSA
June 28, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
June 24, 2019
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
June 24, 2019
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
June 19, 2019
Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
June 14, 2019
Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
June 13, 2019
Bristol-Myers Squibb Announces Dividend
June 13, 2019
New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
June 6, 2019
Bristol-Myers Squibb to Announce Results for Second Quarter 2019 on July 25, 2019
June 5, 2019
Bristol-Myers Squibb Announces Post-Closing Leadership Team
June 4, 2019
Bristol-Myers Squibb to Take Part in Goldman Sachs 40th Annual Global Healthcare Conference
June 3, 2019
Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab)
June 3, 2019
Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019
May 24, 2019
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
May 16, 2019
Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
May 14, 2019
Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What It’s Like to Live with Cancer Today
May 14, 2019
Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference
May 9, 2019
Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
May 8, 2019
Bristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes
May 1, 2019
Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes
May 1, 2019
Bristol-Myers Squibb Company Announces Launch of Private Offering of Senior Unsecured Notes
April 25, 2019
Bristol-Myers Squibb Reports First Quarter Financial Results
April 17, 2019
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
April 12, 2019
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
April 11, 2019
Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
April 2, 2019
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
March 29, 2019
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
March 29, 2019
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
March 25, 2019
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials
March 19, 2019
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
March 7, 2019
Bristol-Myers Squibb Announces Dividend
March 7, 2019
Bristol-Myers Squibb to Announce Results for First Quarter 2019 on April 25, 2019
March 6, 2019
Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference
March 6, 2019
Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
March 5, 2019
Bristol-Myers Squibb to Take Part in the Cowen and Company 39th Annual Health Care Conference
February 28, 2019
Bristol-Myers Squibb Issues Statement in Response to Starboard’s Letter
February 22, 2019
Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene
February 20, 2019
Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
February 14, 2019
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
February 11, 2019
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
February 11, 2019
European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
February 7, 2019
Bristol-Myers Squibb to Take Part in Guggenheim Healthcare Talks Idea Forum
January 24, 2019
Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call
January 24, 2019
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
January 14, 2019
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
January 5, 2019
Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare Conference
January 3, 2019
Bristol-Myers Squibb Provides 2019 EPS Guidance
January 3, 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
January 2, 2019
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia